Keyphrases
Neutralizing Antibodies
100%
COVID-19
100%
Therapeutic Monoclonal Antibody
100%
E484K
87%
Monoclonal Antibody
50%
Virus
37%
Resistance mutations
37%
Viral Clearance
25%
Antibody Resistance
25%
Bamlanivimab
25%
Antibody Response
12%
Specific Monoclonal Antibodies
12%
Next-generation Sequencing
12%
Between-host
12%
Randomized Placebo-controlled Trial
12%
Host Immune Response
12%
Clinical Treatment
12%
Antiviral Treatment
12%
Viral Evolution
12%
Method Study
12%
Serum Neutralizing Antibodies
12%
Plasma Viral Load
12%
Virus Neutralization
12%
S Gene
12%
Resistant Variants
12%
Nasopharyngeal Swab
12%
Emerging Resistance
12%
Treatment Emergent
12%
SARS-CoV-2 RNA
12%
Anti-SARS-CoV-2 Monoclonal Antibodies
12%
Anterior Nasal Swab
12%
ACTIV-2
12%
Emerging Drug Resistance
12%
RNA Testing
12%
Immunology and Microbiology
Antibody Response
100%
Neutralizing Antibody
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Monoclonal Antibody Therapy
100%
Monoclonal Antibody
62%
Antibody Titer
50%
Virus
37%
Viral Clearance
25%
Next Generation Sequencing
12%
Host Immune Response
12%
Neutralization
12%
Viral Load
12%
Drug Resistance
12%
Virus Evolution
12%
Ribonucleic Acid
12%
Pretreatment
12%